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Abstract
Adenovirus (Ad) efficiently delivers its DNA genome into a variety of cells and tissues, provided that
these cells express appropriate receptors, including the coxsackie-adenovirus receptor (CAR), which
binds to the terminal knob domain of the viral capsid protein fiber. To render CAR-negative cells
susceptible to Ad infection, we have produced a bispecific hybrid adapter protein consisting of the
amino-terminal extracellular domain of the human CAR protein (CARex) and the Fc region of the
human immunoglobulin G1 protein, comprising the hinge and the CH2 and CH3 regions. CARex-Fc
was purified from COS7 cell supernatants and mixed with Ad particles, thus blocking Ad infection of
CAR-positive but Fc receptor-negative cells. The functionality of the CARex domain was further
confirmed by successful immunization of mice with CARex-Fc followed by selection of a monoclonal
anti-human CAR antibody (E1-1), which blocked Ad infection of CAR-positive cells. When mixed with
Ad expressing eGFP, CARex-Fc mediated an up to 250-fold increase of transgene expression in
CAR-negative human monocytic cell lines expressing the high-affinity Fcgamma receptor I (CD64) but
not in cells expressing the low-affinity Fcgamma receptor II (CD32) or III (CD16). These results open
new perspectives for Ad-mediated cancer cell vaccination, including the treatment of acute myeloid
leukemia.
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Adenovirus (Ad) efficiently delivers its DNA genome into a variety of cells and tissues, provided that these
cells express appropriate receptors, including the coxsackie-adenovirus receptor (CAR), which binds to the
terminal knob domain of the viral capsid protein fiber. To render CAR-negative cells susceptible to Ad
infection, we have produced a bispecific hybrid adapter protein consisting of the amino-terminal extracellular
domain of the human CAR protein (CARex) and the Fc region of the human immunoglobulin G1 protein,
comprising the hinge and the CH2 and CH3 regions. CARex-Fc was purified from COS7 cell supernatants and
mixed with Ad particles, thus blocking Ad infection of CAR-positive but Fc receptor-negative cells. The
functionality of the CARex domain was further confirmed by successful immunization of mice with CARex-Fc
followed by selection of a monoclonal anti-human CAR antibody (E1-1), which blocked Ad infection of
CAR-positive cells. When mixed with Ad expressing eGFP, CARex-Fc mediated an up to 250-fold increase of
transgene expression in CAR-negative human monocytic cell lines expressing the high-affinity Fcg receptor I
(CD64) but not in cells expressing the low-affinity Fcg receptor II (CD32) or III (CD16). These results open
new perspectives for Ad-mediated cancer cell vaccination, including the treatment of acute myeloid leukemia.
Adenoviruses (Ad) carrying therapeutic genes are currently
among the leading candidate vectors for gene therapy and have
been used to transduce numerous types of tissues and cell
lines, although with varying efficiency. The efficacy of Ad entry
is a major determinant of transgene expression. Entry of sub-
group C Ad, including the currently used Ad2 and Ad5, de-
pends on a primary Ad receptor, the coxsackie-adenovirus
receptor (CAR) protein (5, 53). Secondary Ad receptors have
earlier been identified as avb3- and avb5-type integrins (63).
While the primary receptor is responsible for virus attachment
by binding to the distal portion of the Ad fiber protein, the
integrins bind to the RGD motif of the capsid protein penton
base, thus mediating virus uptake into the cells by receptor-
mediated endocytosis (56, 59). Binding assays using radiola-
beled virions or purified fiber protein demonstrated that dif-
ferent cell cultures express variable amounts of primary Ad
type C receptor(s) (12, 48, 63, 65). In polarized epithelial cells,
the availability of CAR seems to be a limiting step to successful
gene expression (58). CAR expression levels also seem to be
limiting in brain tissue (10), skeletal muscle (1, 39), endothelial
and smooth muscle cells (65), and cells of hematopoietic origin
including human leukocytes (3, 27, 48). Furthermore, the ex-
pression levels of the primary receptor were found to vary
considerably among tumors of different origins, including he-
matopoietic malignancies (9, 11, 18, 61), human melanoma cell
cultures (26), bladder cancer cells (35), and ovarian tumors
(30).
Even cells lacking CAR and/or av integrin expression can be
infected with high doses of vectors (reference 26 and unpub-
lished data). However, a more economical and reliable proce-
dure is to broaden the tropism of Ad vectors. The host range
of Ad can be modified by three means: genetic or biochemical
alterations of the Ad fiber protein or the use of bifunctional
reagents. Genetic alterations include modifications of capsid
fiber proteins, introducing new peptide sequences into the HI
loop of the fiber knob (13, 31, 42) and insertion of a 10-amino-
acid peptide linker sequence followed by the integrin-binding
RGD motif at the carboxy terminus of the Ad5 fiber protein
(66). Alternatively, the coding sequence for a polylysine stretch
can be inserted at the C-terminal end of the fiber gene to allow
binding to cells expressing heparin-binding motifs (64). A dif-
ferent approach includes the exchange of fiber of the com-
monly used Ad2/5 serotype with fiber of alternative serotypes
such as Ad11 and Ad35 (20, 32, 41, 50), facilitating expression
in hematopoietic cell lines (46) and with moderate success also
in CD341 cells (47). Biochemical alterations include the cou-
pling of asialoglycoprotein-polylysine conjugates to wild-type
Ad5 (67) or formulation of Ad complexes with polycationic
polymers and cationic lipids (17). In addition, bispecific anti-
bodies with specificities to av integrin (65) or CD3 (62) and a
second specificity to a FLAG epitope inserted in the penton
base have been reported. Finally, bispecific proteins containing
an Ad5 fiber-specific blocking antibody either fused or chem-
ically coupled with receptor target-specific molecules like fo-
late (15), epidermal growth factor (EGF) (60), fibroblast
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growth factor (22), CD40 (51), and the pancarcinoma antigen
EpCAM (23), have been introduced.
In this study, we have produced a bispecific protein, CARex-
Fc, with defined specificities and high affinities to both Ad
capsid and cell surface Fcg receptor I. The CARex-Fc fusion
protein consists of the ectodomain of CAR fused to the im-
munoglobulin Fc domain. The protein was produced in COS7
cells and purified by affinity chromatography. CARex-Fc effi-
ciently blocked transgene expression of a recombinant Ad ex-
pressing enhanced green fluorescent protein (eGFP) in A549
human lung carcinoma cells. The CARex-Fc protein was tested
for its ability to redirect AdCMV-eGFP-mediated expression
to cells lacking CAR expression but expressing one of the Fcg
receptors. In cells expressing high levels of the high-affinity Fcg
receptor I, CARex-Fc led to an up to 250-fold increase of
eGFP expression. Moderate eGFP expression was obtained in
cells with low levels of cell surface CD64 expression. No eGFP
expression was obtained in cells expressing the low-affinity Fcg
receptors II and III, demonstrating the selectivity of CARex-
Fc. In addition, the CARex-Fc fusion protein was used for
immunization of mice and selection of an Ad infection-block-
ing monoclonal antibody specific for human CAR.
MATERIALS AND METHODS
Cell culture. Cells were grown in RPMI 1640 plus 10% fetal calf serum (FCS)
unless indicated differently. Jurkat (acute T-cell leukemia), U937 (D) (monocytic
lymphoma), Daudi (Burkitt’s B-lymphoma), and K562 (chronic myelogenous
leukemia) cells were provided by F. Nestle, Department of Dermatology, Uni-
versity of Zu¨rich, Zu¨rich, Switzerland. HL-60 (promyelocytic leukemia) cells
were obtained from A. Ziogas, Medical Virology, University of Zu¨rich. Raji
(Burkitt’s B-lymphoma) cells were obtained from O. Georgiev, Institute of Mo-
lecular Biology, University of Zu¨rich. U937 (H) (monocytic lymphoma), THP-1
(acute monocytic leukemia), Kasumi-1 (acute myeloid leukemia [AML]), and
SigM5 (AML) cells, as well as primary AML cells were kindly provided by G.
Schoedon and Peghini, Department of Medicine, University of Zu¨rich. THP-1
cells were cultured in Iscove modified Dulbecco medium (IMDM) plus 10%
FCS, whereas SigM5 cells were propagated in IMDM plus 20% human serum.
All cell lines were originally purchased from the American Type Culture Col-
lection, with exception of Kasumi-1 (Department of Human and Animal Cell
Cultures, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braun-
schweig, Germany) and SigM5 (57). Primary patient AML cells were isolated
using the standard therapeutic leukapheresis procedure after obtaining informed
consent, typed, and frozen in IMDM plus 50% pooled human serum. Short
cultures of 2 days were performed in IMDM plus 10% FCS. Natural killer cells
were isolated as described elsewhere (45) from the blood of healthy volunteers
and were propagated in AIM-V medium containing 10% human serum, 10%
leukocyte-conditioned medium (LCM), 2% HEPES, 1% sodium pyruvate, 1%
glutamine, 1% nonessential amino acids, 1% penicillin-streptomycin and 100 U
of interleukin-2 per ml. Human 911 cells were received from Fallaux et al. (16)
and grown in Dulbecco’s modified Eagle’s medium (DMEM) plus 10% FCS.
COS7 cells were kindly provided by S. Nagata, Osaka University, Osaka, Japan,
and were grown in low-FCS medium (TurboDoma containing 1% FCS; Cell
Culture Technologies, Gravesano, Switzerland). DO4 cells producing CTLA4-
immunoglobulin G1 (IgG1) fusion protein specific for B7 (14) were obtained
from R. Dummer, Department of Dermatology, University of Zu¨rich, and were
grown in DMEM plus 10% FCS. The A549 human lung carcinoma cell line was
received from P. Sonderegger, Biochemisches Institut, University of Zu¨rich, and
was grown in DMEM plus 10% FCS. All cell lines were routinely screened for
the absence of mycoplasma contamination.
Construction of pCMV1-CARex-Fc. The pCMV1-Fc expression plasmid was
originally constructed and kindly provided by X. He, Children’s Hospital, Har-
vard Medical School, Boston, Mass. (unpublished results). The plasmid contains
a 699-bp Fc fragment derived from the human IgG1 cDNA, encoding the hinge,
CH2, and CH3 regions, which was amplified by the use of sequence-specific
primers and PCR. In addition to the polylinker, the plasmid contains the human
cytomegalovirus (CMV) enhancer/promoter, a polyadenylation sequence of the
human growth hormone, and a simian virus 40 origin of replication.
The sequence encoding the first 236 amino acids of the extracellular domain
of human CAR (including the endogenous Kozak motif and the N-terminal
signal sequence) was amplified from cDNA synthesized from total RNA of 911
cells by using synthetic oligonucleotides corresponding to the published sequence
(5). The PCR product was digested with HindIII and Xbal to allow in-frame
fusion to the human IgG1-Fc sequence. The fusion junctions were verified by
sequencing.
PAGE and Western blotting. For analysis of the CARex-Fc protein, COS7
cells were transiently transfected as described elsewhere (24). To reduce the
levels of unrelated proteins, the medium from transfected COS7 cells was re-
placed 1 day after transfection with TurboDoma medium lacking FCS. Super-
natants of transfected cells and purified CARex-Fc protein were analyzed by
polyacrylamide gel electrophoresis (PAGE) (33) followed by Coomassie blue
staining or by Western blotting of electrotransferred protein to Immobilon-P
membranes. Membranes were saturated in Tris-buffered saline plus 0.1% Tween
20 (TBS-T) containing 5% dry milk and incubated with fluorescein isothiocya-
nate (FITC)-conjugated rabbit anti-human IgG (Dako, Copenhagen, Denmark)
for 1 h. Immunoreactivity was scored using a Fluoroimager 595 (Molecular
Dynamics, Amersham, Berkhamsted, United Kingdom).
For analysis of CAR protein, cells were lysed in NETN (10 mM Tris [pH 8.0],
200 mM NaCl, 1 mM EDTA, 0.5% NP-40) containing 1 mM phenylmethylsul-
fonyl fluoride. Protein concentrations were determined using the bicinchoninic
acid assay (BCA; Pierce, Rockford, Ill.), and protein separation was performed
by sodium dodecyl sulfate (SDS)-PAGE (10% polyacrylamide) under nonreduc-
ing conditions. After transfer to Immobilon-P membranes, the blots were
blocked in 5% dry milk in TBS-T, and incubated with mouse monoclonal anti-
body E1-1 (1:20 dilution of hybridoma supernatant) for 1 h and then with
horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim
Biochemicals, Indianapolis, Ind.) for 1 h. Immunoreactivity was determined
using the enhanced chemiluminescence Western blotting detection system (Am-
ersham).
CARex-Fc protein purification. Low-FCS supernatant containing CARex-Fc
protein was adsorbed to protein G-Sepharose (Amersham Pharmacia). Follow-
ing washing with phosphate-buffered saline (PBS), bound protein was eluted
using 0.15 M glycine-HCl (pH 2.8) and immediately neutralized with 1 M Tris
(pH 9.5). Eluted material was concentrated using centrifugal filter devices (Mil-
lipore, Bedford, Mass.), dialyzed against PBS, and kept frozen in aliquots. The
protein concentration of purified CARex-Fc was determined by the BCA assay.
Immunization and hybridoma production. BALB/c mice were injected twice
intramuscularly with 30 mg of the pCMV1-CARex-Fc expression plasmid at
2-week intervals followed by a single 100-mg injection after 2 weeks. Sera from
tail veins were tested by cytofluorometric analysis for the presence of anti-CAR
antibodies. The mice were further boosted with one injection of a protein-
adjuvant mix (270 mg of CARex-Fc mixed with 270 mg of polyadenylic-polyuri-
dylic acid adjuvant [Sigma, St. Louis, Mo.]) after an additional 2 weeks and then
2 weeks later with an injection of 100 mg of protein without adjuvant 3 days
before cell fusion. Spleen cell preparation and fusion with P3-X63Ag myeloma
cells (a kind gift from H. Hengartner, Experimental Immunology, University of
Zu¨rich, Zu¨rich, Switzerland) were performed as described previously (25). Su-
pernatants of HAT (Gibco-BRL)-resistant colonies were screened by a cytoflu-
orometric assay using 911 cells. The isotype of the E1-1 antibody was determined
to be mouse IgG1, using a hemagglutination test (Serotec, Oxford, United
Kingdom). For purification of E1-1 antibody, the hybridoma cells were cultured
in TurboDoma medium and antibody was isolated by protein G-Sepharose
chromatography as described above.
Immunoreagents and flow cytometric analysis. CTLA4-IgG1 fusion protein
specific for B7 (14) was produced and purified as described for E1-1 antibody.
The mouse monoclonal antibody RmcB specific for human CAR (5) was pro-
vided by R. Finberg, Dana-Farber Cancer Institute, Boston, Mass. FITC-labeled
anti-human CD16 (30624X), CD32 (30934X), and CD64 (31844X) and appro-
priate isotype controls were purchased from Pharmingen, San Diego, Calif., and
secondary fluorochrome conjugates were purchased from Serotec.
For cytofluorometric analysis of adherent 911 cells, subconfluent cells were
washed with PBS and detached by treatment with PBS–20 mM EDTA. Approx-
imately 106 cells were incubated with either 50 ml of hybridoma supernatant or
1 mg of various antigen-specific antibodies in 250 ml of balanced salt solution
(BSS)–5% FCS (BSS is 0.14 M NaCl, 1 mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4,
0.3 mM NaH2PO4, and 0.4 mM KH2PO4 [pH 6.9]) for 30 min on ice. If unlabeled
primary antibodies were used, the cells were washed by pelleting in BSS–2%
FCS, incubated with 1 mg of phycoerythrin-labeled secondary conjugates, and
washed again before being subjected to cytofluorometric analysis (Epics XL;
Coulter, Miami, Fla.). Fluorescence-activated cell sorter (FACS) measurements
were performed with 10,000 viable cells per sample. For eGFP expression anal-
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ysis, A549 cells were transduced with AdCMV-eGFP and 2 days later the cells
were detached and washed as described above. To analyze whether Ad binding
competed with E1-1 binding to 911 cells, cells were detached, incubated with
increasing amounts of AdCMV–muB7-1 for 60 min on ice, washed, and stained
with E1-1 as described above.
Recombinant Ad vectors and inhibition of Ad-mediated cell transduction.
Recombinant E1- and E3-deleted Ad vectors were constructed and CsCl purified
as described previously (26). Viral titers were determined by incubating 2 ml of
medium on 911 cell layers in six-well plates (e.g., 6 3 109 PFU/ml for AdCMV-
eGFP [kindly provided by C. Kuhl, Institute of Molecular Biology, University of
Zu¨rich, Zu¨rich, Switzerland] and 1.2 3 1010 PFU/ml for AdCMV-muB7-1, ex-
pressing the mouse B7-1 transgene). The virion concentration of AdCMV-eGFP
was determined by the method of Maizel et al. (37) and found to be 3.4 3 1011
particles/ml.
For transduction inhibition assays using E1-1 or CARex-Fc, A549 monolayer
cultures were grown to 30% confluence in six-well plates. For E1-1 blocking
assays, the medium was replaced with 0.5 ml of E1-1 hybridoma supernatant or
with binding medium (PBS plus DMEM–10% FCS, 1:1 mix) containing purified
E1-1 and the cells were incubated on a rocking platform for 2.5 h on ice.
Reporter AdCMV-eGFP was added at a multiplicity of infection (MOI) of 100,
and the cells were incubated for an additional 2.5 h on ice. They were then
washed twice with cold binding medium, and normal cell culture medium in-
cluding E1-1 antibody or control antibody was supplied, followed by incubation
for 2 days at 37°C in a CO2 incubator. To assay CARex-Fc-mediated blocking,
purified CARex-Fc protein was mixed with reporter Ad for 60 min on ice and
then added to A549 cells; this was followed by the washing procedure and
analysis of transgene expression as described above.
CARex-Fc-mediated enhancement of cell transduction. Hematopoietic cells
were seeded at a concentration of 4 3 105 in 0.5 ml of medium in 12-well plates.
Human serum was replaced with FCS as indicated. AdCMV-eGFP was mixed
with CARex-Fc protein in a volume of 20 ml of medium and added to the cells.
After overnight incubation, the volume was increased to 1 ml, and eGFP expres-
sion was analyzed 48 h postinfection. For inhibition of Fcg receptor-dependent
infections, THP-1 cells were preincubated on ice with either 2mg of CTLA4-lg or
1 mg of a mouse anti-human CD64 antibody (31841A; Pharmingen) for 30 min,
washed, and processed as described above.
RESULTS
Expression and purification of the CARex-Fc fusion protein.
An expression plasmid encoding the ectodomain of the human
Ad receptor CAR fused to the human IgG1 Fc domain was
constructed for two reasons. First, we wanted to use such a
protein for the production of new and eventually neutralizing
CAR-specific monoclonal antibodies. Existing CAR-specific
antibodies such as the RmcB produced by Hsu et al. (28)
apparently do not block Ad infection (R. Finberg, personal
communication). Second, we reasoned that such a bispecific
protein might allow targeting of Ad to cells that express Fcg
receptors, but lack CAR expression. A PCR-amplified cDNA
sequence corresponding to amino acids 1 to 236 of the human
CAR sequence (including the endogenous Kozak motive and
the N-terminal signal sequence of 14 amino acids which is
cleaved off in the endoplasmic reticulum) was cloned in frame
into the pCMV1-IgFc expression plasmid containing the hu-
man IgG1 sequence (Fig. 1A). The extracellular sequence of
CAR contains the two Ig-like domains D1 and D2 (Fig. 1B),
responsible for binding to Ad and group B coxsackievirus (5,
19). The human IgG1 Fc sequence encodes 232 amino acids
comprising the hinge, CH2, and CH3 regions. The mature
fusion protein is expected to consist of 455 amino acids with a
calculated molecular mass of 50.7 kDa. Expression of the fu-
sion protein was controlled by the human CMV promoter and
an SV40 origin of replication (21) mediating efficient produc-
tion of the CARex-Fc fusion protein from transiently trans-
fected simian COS7 cells. Supernatants of transfected COS7
cells and purified fusion protein were analyzed by SDS-PAGE
under reducing conditions and by Western blotting using an
FITC-labeled rabbit anti-human Ig. Specific staining of a dif-
fuse band migrating as a ;60-kDa species was found in crude
supernatants of COS7 cells transfected with the pCMV1-
CARex-Fc expression plasmid (Fig. 1C, lanes 3 and 4) but not
in supernatants of mock transfected COS7 cells (lane 7) or cell
culture medium alone (lane 1). The difference between the
apparent and calculated molecular masses and also the pres-
ence of a faster-running species may be due to N-linked gly-
cosylation described previously for full-length CAR (53). As a
control, the fusion protein CTLA4-Ig (14, 36), of ;50 kDa, is
FIG. 1. Production of CARex-Fc fusion protein. (A) The expres-
sion plasmid pCMV1-CARex-Fc was generated by fusing the cDNA
encoding the 236 N-terminal amino acids, including the signal peptide
of the human CAR protein, via a linker of 1 amino acid with the cDNA
encoding 232 amino acids of the human IgG1 Fc polypeptide. (B) The
mature, signal sequence-processed protein contains the extracellular
two Ig-like domains D1 and D2 of CAR fused to the hinge, CH2, and
CH3 regions of IgG1 resulting in a presumably secreted protein of 455
amino acids (aa). (C) Western blot analysis of CARex-Fc protein.
COS7 cells were transiently transfected with pCMV1-CARex-Fc for 1
day (lane 2), 3 days (lane 3), or 5 days (lane 4) or were mock trans-
fected (lane 7). Cell supernatants (30 ml) were subjected to SDS-
PAGE. In addition, 1.5 mg of purified CARex-Fc (lane 5), 30 ml of
DMEM plus 10% FCS (lane 1), and supernatant of stably transfected
myeloma cells containing CTLA4-IgG1 (lane 6) were analyzed as con-
trols. Human Igs were detected with FITC-labeled rabbit anti-human
Ig antibody. (D) Analysis of purified recombinant CARex-Fc by PAGE
and Coomassie blue staining. Purified CARex-Fc protein (3 mg) was
loaded under reducing (lane 1) or nonreducing (lane 2) conditions.
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shown in lane 6 (Fig. 1C). The amount of CARex-Fc protein in
the supernatant increased over 5 days of cell growth, allowing
the isolation of 4.5 mg of pure CARex-Fc protein from 1 liter
of culture supernatant (Fig. 1D). Under nonreducing electro-
phoresis conditions, CARex-Fc migrated with molecular mass
of ;120 kDa, probably disulfide bonded by cysteines of the
hinge region (Fig. 1D, lane 2). In addition, CARex-Fc behaved
as a ;120-kDa species when analyzed on a gel filtration col-
umn at physiological salt concentrations (S. Hemmi, unpub-
lished results).
Production of the human CAR-specific monoclonal antibody
E1-1 and inhibition of Ad-mediated cell transduction by E1-1
and CARex-Fc protein. To produce monoclonal antibodies
with specificity for human CAR, BALB/c mice were immu-
nized and boosted first with the CAR expression plasmid, and
then with purified CARex-Fc protein as described in Materials
and Methods. Spleen cells of immunized mice were fused with
P3-X63Ag myeloma cells, and hybridoma supernatants were
first screened by cytofluorometric analysis for positive staining
of 911 cells, which have high levels of CAR and then tested for
Ad-blocking activity. The monoclonal antibody E1-1 turned
out to have both features. When tested for cell binding, the
E1-1 antibody stained 911 cells and L929.CAR mouse fibro-
blasts stably expressing the human CAR protein but not pa-
rental L929 cells or CAR-negative CHO cells (Fig. 2A). The
staining pattern was comparable to that of RmcB (references 5
and 28 and results not shown). In addition, when performing
Western blotting using protein extracts from different cells, the
monoclonal E1-1 antibody recognized a single protein of ;50
kDa (Fig. 2B), similar to results described for RmcB under
nonreducing conditions (52). Even at the lowest protein
amount of 911 or L929. CAR cell extracts tested (0.3 mg), we
obtained a clear signal of the 50-kDa protein band (Fig. 2B,
lanes 1 and 8, respectively). The additional two faster-running
bands seen with the higher concentrations of extracts from
L929.CAR cells may represent degradation products or pro-
teins derived from additional RNA splicing variants (lane 6).
Accordingly, even the largest amounts of protein extracts from
CHO or L929 cells (30 mg) gave no signal, suggesting that the
50-kDa band was CAR (lanes 4 and 5, respectively).
We then tested if E1-1 and CARex-Fc inhibited Ad-medi-
ated transgene expression of a recombinant Ad expressing
eGFP in A549 lung carcinoma cells (which are negative for
the high-affinity Fcg receptor CD64). Blocking or competi-
tion experiments were performed on ice to prevent possible
internalization of ligands. As shown in Fig. 3A, both E1-1
and CARex-Fc reduced eGFP expression when the cells were
treated with supernatant containing the E1-1 antibody (left
panel) or when virus was preincubated with 1 mg of purified
CARex-Fc protein (right panel). To quantitate this inhibition,
purified E1-1 antibody and CARex-Fc protein were titrated
and eGFP expression was determined (Fig. 3B and C, respec-
tively). We found that 440 ng of E1-1 antibody and 11 ng of
CARex-Fc protein resulted in a 50% inhibition of Ad-medi-
ated eGFP expression, with the latter corresponding to a 200-
fold molar excess of protein over virus particles. A maximal
input of 20 mg of E1-1 antibody and 10 mg of CARex-Fc
protein resulted in inhibition of 98% for both proteins.
Since the E1-1 antibody was capable of blocking Ad binding,
we asked whether Ad binding would block E1-1 staining. 911
cells were incubated with increasing amounts of AdCMV-
muB7-1, washed, and stained with E1-1 antibody. At the high-
est MOI (5,000) the mean fluorescence of E1-1 was reduced to
background levels, confirming that CAR is a major determi-
nant of Ad binding to these cells (Fig. 3D). Together, these
results indicated that both the E1-1 antibody and the CARex-
Fc fusion protein were functional CAR-specific reagents.
Binding of CARex-Fc to cells expressing CD64 high-affinity
Fcg receptor I. Using the E1-1 antibody, we next analyzed
whether CARex-Fc fusion protein bound to cells expressing
either the high-affinity Fcg receptor I (CD64) or the low-
affinity Fcg receptors II and III (CD32 and CD16, respectively).
Using specific anti-Fcg receptor antibodies, expression levels
of CD16, CD32, and CD64 were determined by cytofluoromet-
ric analysis on primary NK cells, primary AML cells, and a
panel of hematopoietic cell lines listed in Table 1. CAR ex-
pression was measured using the E1-1 anti-CAR antibody both
for cytofluorometric and Western blot (data not shown) anal-
yses. Two cell lines, the monocytic lymphoma U937 (D) and
the monocytic leukemia THP-1, and also patient-derived pri-
mary AML cells showed relatively high expression levels of
both CD32 and CD64 but undetectable levels of CAR (Fig. 4).
All cell lines were then tested for binding of CARex-Fc in a
FIG. 2. Specificity of the E1-1 anti-human CAR monoclonal anti-
body. (A) Cytofluorometric analysis of CAR expression levels in dif-
ferent cell lines, using the E1-1 antibody. White histograms show
background staining obtained using isotype control antibodies, and
shaded histograms show CAR-specific staining. (B) Western blot anal-
ysis using E1-1 antibody and 0.3, 3, and 30 mg of protein lysate of 911
cells (lanes 1 to 3), 30 mg of protein lysate of CHO cells (lane 4), 30 mg
of protein lysate of L929 cells (lane 5), and 30, 3, and 0.3 mg of protein
lysate of L929.CAR cells (lanes 6 to 8, respectively).
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triple-sandwich staining assay. The first incubation was with
CARex-Fc, and the second incubation was with the mouse
E1-1 antibody followed by a phycoerythrin-labeled rabbit anti-
mouse Ig conjugate. The FACS analyses in Fig. 5 shows three
representative examples of cells with negative endogenous
CAR staining. Daudi cells (negative for all three types of Fcg
receptor) and K562 cells (positive for CD32) showed no
CARex-Fc binding. In contrast, THP-1 cells, which were CD32
and CD64 positive, also bound CARex-Fc but gave no signal in
the absence of CARex-Fc. Taken together, these results dem-
onstrated that CD64-positive cells but not CD16- and CD32-
positive cells bound soluble CARex-Fc.
CD64- and CARex-Fc-mediated increase of Ad transgene
expression. To test whether CARex-Fc protein allowed im-
proved Ad-mediated eGFP expression in cells containing one
of the Fcg receptors, the cells listed in Table 1 were incubated
with AdCMV-eGFP at an MOI of 10, either alone or premixed
with 1.0 mg of CARex-Fc protein. eGFP staining was analyzed
48 h postinfection. A representative collection of histograms
using four different types of cells (Jurkat, HL-60, THP-1, and
primary AML) is shown in Fig. 6A. For HL-60, THP-1, and
primary AML cells, virus alone gave rise to a small number of
cells expressing eGFP at low mean fluorescence values. In
contrast, premixing of Ad with CARex-Fc resulted in a strong
increase of eGFP expression with 90% (THP-1) or 75%
(AML) of the cells shifted to eGFP expression at high mean
fluorescence values. When CARex-Fc was replaced by compa-
rable amounts of the control CTLA4-Ig protein, which binds to
the Fcg receptor but not to Ad, no effect on eGFP expression
was observed (data not shown), suggesting that ligation of the
high-affinity Fcg receptor alone does not induce uptake of Ad.
For HL-60 cells, only about 20% of the cells showed a similar
increase of expression, most probably reflecting the cell pop-
ulation expressing CD64. Jurkat cells demonstrated no change
of eGFP expression on addition of CARex-Fc protein. A sys-
tematic analysis of eGFP expression levels of THP-1 cells as a
function of CARex-Fc levels and Ad MOIs is depicted in Fig.
6B. MOIs of 3.3, 10, 30, and 90 were combined with different
amounts of CARex-Fc, ranging from 882 to 3.6 ng, and the
relative eGFP expression on day 2 postinfection was deter-
mined. For all MOIs used, a strong increase in eGFP expres-
sion was found, ranging from 30-fold at an MOI of 3.3 to
100-fold at MOIs of 30 and 90. For MOIs of 3.3, 10, and 30,
peak induction was obtained with 294 or 98 ng of purified
CARex-Fc protein, which corresponded to a protein/virus par-
ticle ratio of 6,400 to 2,100. Maximal (250-fold) induction was
FIG. 3. Functional properties of E1-1 and CARex-Fc. (A) Inhibi-
tion of Ad-mediated eGFP expression by E1-1 anti-human CAR
monoclonal antibody and CARex-Fc. A549 cells were either preincu-
bated with 250 ml of E1-1 antibody supernatant or control antibody
(left panel) and then incubated with virus or mixed with virus previ-
ously incubated on ice with 1 mg of CARex-Fc or CTLA4-Ig (right
panel) protein. All incubations were performed for 2.5 h on ice, and
the virus was used at an MOI of 100. The cells were then washed twice,
and culture medium including E1-1, CARex-Fc, or control proteins
was supplied. The cells were incubated for 2 days and analyzed for
eGFP expression. (B and C) Quantification of the inhibitory effects of
E1-1 (B) and CARex-Fc (C). Fivefold dilutions of purified E1-1 anti-
body or CARex-Fc protein (M) or control control proteins (V) were
used as described for panel A. The eGFP expression index was calcu-
lated from the ratios of the mean eGFP expression measured in cells
incubated either with E1-1 plus AdCMV-eGFP or CARex-Fc plus Ad-
CMV-eGFP to the value in those treated with AdCMV-eGFP alone.
Expression values represent the mean of triplicates including standard
deviations. (D) Inhibition of E1-1 anti-human CAR monoclonal anti-
body binding to 911 cells by Ad. Cells were stained with E1-1 antibody
following preincubation in the cold with the indicated amounts of
AdCMV-muB7-1. Fluorescence intensities of stainings with isotype
and specific antibody are given as the mean of triplicates including
standard deviations of the mean.
484 EBBINGHAUS ET AL. J. VIROL.
obtained when the analysis was performed on day 1 with an
MOI of 90, and the minimal amount of CARex-Fc protein
which still increased the eGFP expression level was 130 pg
(data not shown). At all MOIs used except 90, the largest
amount of CARex-Fc protein (882 ng) gave a weaker stimu-
lation than did optimal amounts of CARex-Fc, presumably due
to binding competition of soluble CARex-Fc protein with vi-
rus-bound CARex-Fc for the high-affinity Fcg receptor. Like-
wise, high concentrations of CARex-Fc also had an inhibitory
effect on Jurkat, U937 (H) and K562 cells (summarized in
Table 1). Weak signals for endogenous CAR were seen for
Jurkat and K562 cells in Western blots (data not shown) but
not in FACS experiments. Surprisingly, Raji cells, which yield-
ed a robust CAR signal in both assays, did not show any
inhibitory effect. Ramos cells were completely resistant to Ad-
mediated eGFP expression, possibly because they were shown
to stain negative for several surface integrins (44).
Enhanced eGFP expression was obtained by two different
protocols. Either CARex-Fc protein was premixed briefly with
Ad and then added to cells and left on the cells for 48 h or cells
were first incubated on ice with CARex-Fc only, washed, and
incubated with virus (data not shown). The results of the two
methods were comparable, suggesting that the CARex-Fc fu-
sion protein was functionally independent of whether it was
first bound to Ad or to the target cells.
Of the 11 cell lines and 2 primary cell cultures of myeloid or
lymphatic origin, 2 cell lines, THP-1 and U937 (D), and one
primary patient-derived AML cell culture showed a high in-
crease of Ad transduction efficiency due to CARex-Fc (Table
1). The CARex-Fc-responsive cells expressed the high-affinity
Fcg receptor CD64 at relatively high levels (Fig. 4). Low levels
of CD64 expression on HL-60, Kasumi-1, and SigM5 cells
correlated with a low but significant increase of CARex-Fc-
mediated expression.
To supply further evidence that the high-affinity Fcg recep-
tor is responsible for mediating the increased transduction
efficiency, premixed virus and CARex-Fc was added to cells
pretreated with either the CTLA4-Ig fusion protein binding to
Fcg receptor or a monoclonal antibody against human CD64
(Fig. 6C and D, respectively). In both cases, a reproducible 33-
and 7-fold reduction of the eGFP expression levels were ob-
FIG. 4. Cytofluorometric analysis of low-affinity (CD16 and CD32)
and high-affinity (CD64) Fcg receptor expression and CAR expression
of primary NK and AML cultures and hematopoietic cell lines. Cells
were stained using either isotype control (white histograms) or specific
FITC-labeled antibodies (CD16, CD32, and CD64) or the E1-1 anti-
body in combination with phycoerythrin-conjugated rabbit anti-mouse
IgG (black histograms).
TABLE 1. Expression of low and high-affinity Fcg receptors and CAR and effects of CARex-Fc on Ad-mediated transduction
Cell line
Expression of:
Transduction
with or without CARex-FcCD16
(FcgRIII)
CD32
(FcgRII)
CD64
(FcgRI)
CAR
(FACS)
CAR
(Western)
Primary NK cells 11 2 2 2 2 No change
Jurkat (acute T-cell leukemia) 2 2 2 6a 6a 40% inhibition at highest CARex-Fc
Daudi (Burkitt’s B lymphoma) 2 2 2 2 2 No change
Raji (Burkitt’s B lymphoma) 2 11 2 1 1 No change
Ramos (Burkitt’s B lymphoma) 2 2 2 2 1 No change
K562 (chronic myelogenous leukemia) 2 11 2 2 1 20% inhibition at highest CARex-Fc
U937 (H) (monocytic lymphoma) 2 2 2 2 2 20% inhibition at highest CARex-Fc
U937 (D) (monocytic lymphoma, alternative subline) 2 11 1 2 2 Up to 250-fold increase
HL-60 (promyelocytic leukemia) 2 1 6 2 2 5-fold- increase
SigM5 (AML) 2 1 6 2 2 2–3-fold increase
Kasumi-1 (AML) 2 1 6 2 2 2–3-fold increase
THP-1 (acute monocytic leukemia) 2 11 11 2 2 Up to 250-fold increase
Primary AML cells 2 1 11 2 2 Up to 200-fold increase
a Weak signal.
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served at small amounts of CARex-Fc. Taken together, these
results indicate that the bispecific fusion protein CARex-Fc is
capable of bridging the CD64 surface protein and the Ad fiber
protein and thereby increases Ad infection in these cells.
DISCUSSION
Several approaches have been used to improve the Ad trans-
duction efficiency of cells normally resistant to Ad. In the best
cases, genetically modified Ad vectors containing heterologous
peptides, such as RGD in the HI loop of the fiber (13, 31, 42)
or at the C-terminal end (64, 66), were reported to increase the
transduction efficiency up to 500-fold across a broad range of
cell types. However, cells of hematopoietic origin with low
levels of integrin expression (29) are not expected to be good
targets of RGD-modified Ad. An additional limitation of such
a genetic approach is the small size of the targeting peptide
tolerated by the virus capsid structure (8, 66). Further exten-
sion of productive Ad-cell interactions by selective strategies is
thus important to broaden Ad tropism for medical purposes.
Toward this goal, we have designed bispecific and simple-to-
produce fusion proteins. We have demonstrated that a bispe-
cific fusion protein consisting of the ectodomain of CAR fused
to the immunoglobulin Fc domain improves the transduction
efficiency of hematopoietic cells devoid of the primary Ad
receptor CAR by up to 250-fold. This transduction increase is
highly significant and fully dependent on the presence of high-
affinity Fcg receptor I (CD64). The transduction increase is
significantly reduced by CTLA4-Ig protein or an anti-human
CD64 monoclonal antibody, which bind to the high-affinity Fcg
receptor I. The inclusion of the CAR ectodomain in our fusion
construct is useful since this domain confers high-affinity bind-
ing to the fiber protein of Ad. If all the fibers are decorated
with CARex-Fc, we expect that such modified virus prefers to
bind to Fcg receptors rather than to the receptor of native Ad,
CAR.
Accordingly, we have demonstrated that coincubation of
virus with CARex-Fc strongly reduced Ad-mediated expres-
sion in CAR-positive, Fcg receptor-negative A549 cells, argu-
ing for the correct folding of at least the D1 domain of
CARex-Fc (19). In addition, the successful production of a
virus-neutralizing monoclonal anti-human CAR-specific anti-
body using the CARex-Fc protein to boost the immune re-
sponse, together with the demonstration of direct binding of
the CARex-Fc protein to CD64-positive cells, adds further
evidence for the functionality of our hybrid adapter protein.
Other strategies to alter Ad host range have involved con-
jugates containing blocking anti-Ad fiber knob Fab (15) or an
anti-FLAG epitope antibody (65). Most closely related to our
approach is the use of a bispecific protein consisting of the
neutralizing scFv antibody fragment recognizing the fiber knob
fused to the EGF ligand, termed the adenobody (60). In this
system, viral gene delivery to cells expressing the EGF receptor
was enhanced 16-fold. Since all the cells tested in these exper-
iments also expressed CAR, the contribution of the additional
EGF domain to retargeting Ad was difficult to define. Besides
the EGF receptor, additional receptors like the folate receptor
(15) and CD3 on T lymphocytes (62) have been used as targets
for bispecific conjugates to extend Ad tropism. A similar ap-
proach was described for retroviruses by using a bispecific
soluble virus receptor fused to EGF (6, 49). In this system,
improved transduction was obtained by preincubating cells
with the hybrid protein and then incubating them with vi-
rus. Alternatively, virus was incubated with the fusion pro-
tein and purified and then the complex was added to target
cells.
In contrast to several of the previous reports, our approach
was effective for cells lacking the natural virus receptor. The
presence of the high-affinity Fcg receptor I on the target cells
was sufficient for a robust Ad-mediated gene expression. It is
not known at present if CARex-Fc-modified Ad entered the
CAR-less cells by a clathrin-dependent pathway, which was
suggested to operate for Ad infection of fibroblast-type cells
(59). Possibly, our CARex-Fc-modified Ad is taken up by a
clathrin-independent route similar to Fc receptor-mediated
endocytosis in phagocytic cells (2). This pathway operates in an
actin-dependent manner, typically with particles larger than 0.5
mm. Since the CARex-Fc bridging protein seems to be dimeric,
multiple Ads could become cross-linked and thus might induce
phagocytosis. However, the low-affinity Fcg receptors II and
III, which primarily recognize immune complexes (55), were
inefficient for CARex-Fc-Ad infection, suggesting that the
CARex-Fc-Ad complexes were poorly recognized by the low-
affinity Fcg receptor uptake system. Further experiments are
necessary to clarify the mechanisms of Ad-mediated transgene
delivery into Fcg receptor I-positive cells.
Nonetheless, CARex-Fc-modified Ad may have clinical po-
tential. CD64 is expressed on monocytes, macrophages, and
subtypes of AML cells but not on maturating dendritic cells (7,
43, 55) (Fig. 4). Since global survival rates for patients with
AML are poor, the further development of immunotherapy
and immune vaccine approaches is a valuable goal to pursue
FIG. 5. CARex-Fc binds directly to CD64-positive cells. Daudi,
K562, and THP-1 cells were incubated first with or without CARex-Fc
(shaded and white histograms, respectively) and then with E1-1 and
phycoerythrin-conjugated rabbit anti-mouse IgG.
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(4). The concept of immune gene therapy for cancer is based
on the presumption that the host immune system is capable of
recognizing tumor-associated antigens. For AML, little infor-
mation is available about potential immunostimulatory anti-
gens. Recently, isolation of AML-specific T-cell clones was
reported (38, 40), but no corresponding peptide sequences
have so far been published. High levels of transiently expressed
cytokines and immune modulators might be sufficient to acti-
vate the immune system in vivo and thereby achieve the ther-
apeutic goal (34, 54). Cells of the hematopoietic system are
particularly suitable for gene therapy, since the techniques for
bone marrow and blood cell transplantations are well estab-
lished and, importantly, the transductions can be performed ex
vivo. Primary AML cells can be obtained from patient bone
marrow aspirates or peripheral blood mononuclear cells and
can be kept in culture in the presence of interleukin-3, stem
cell factor, or kit ligand (for a review, see reference 4). How-
ever, none of the currently used gene therapy vectors allow
efficient gene transfer to malignant cells of hematopoietic
origin. Therefore, the development of CARex-Fc for Ad-me-
diated gene transfer provides a promising alternative to spe-
cifically transfer therapeutic genes into CD64-positive AML
malignancies. For other types of malignancies, alternative cell
surface markers may serve as targets. Replacement of the Fc
portion of CARex-Fc with other polypeptide sequences that
bind to surface markers, such as receptor ligands or single-
chain antibodies, may allow the production of a whole range of
bifunctional, soluble Ad receptor-ligand fusion proteins.
FIG. 6. CARex-Fc-mediated increase of Ad transgene expression
in hematopoietic cells. (A) Jurkat, HL-60, THP-1, and primary AML
cells were transduced with AdCMV-eGFP using an MOI of 10 in the
absence (red) or presence (green) of 1 mg of CARex-Fc protein. Cells
alone are shown as solid blue histograms. (B) MOI and CARex-Fc
dose effects on the transduction efficiency of THP-1 cells. Results are
given as means of duplicate determinations of eGFP mean values. The
results of one of three comparable experiments are shown. (C) Inhi-
bition of CARex-Fc-mediated transgene expression by preincubation
of THP-1 cells with 2 mg of CTLA4-Ig for 30 min on ice. Experimental
settings were comparable to those in panel B when using AdCMV-
eGFP at an MOI of 10 and various amounts of CARex-Fc protein. (D)
Inhibition of transgene expression by preincubation of THP-1 cells
with 1 mg of an monoclonal mouse anti-human CD64 antibody.
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ADDENDUM
After submission of this article, another group reported the
use of a bispecific fusion protein consisting of the soluble
truncated form of CAR fused with epidermal growth factor
mediating Ad targeting to epidermal growth factor receptor-
positive cells (13a).
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